SCHEMBL21390327

SCHEMBL21390327

CC(C)O[C@H]1C[C@@H](OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSK P43235 1/20 0.45
OPRM1 P35372 2/20 0.44
OPRL1 P41146 2/20 0.44
NAAA Q02083 3/20 0.42
TMEM97 Q5BJF2 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
FFAR1 O14842 1/20 0.42
DPP4 P27487 1/20 0.41
ACACB O00763 1/20 0.40
AGTR2 P50052 2/20 0.39
TACR1 P25103 2/20 0.38
TSHR P16473 1/20 0.38
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294689 1.00 CTSL (0.45) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL25011406 0.84 CTSL (0.46) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL29284871 0.83 CTSL (0.40) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL28624347 0.83 CTSL (0.45) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL21828151 0.81 CTSL (0.44) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL8345619 0.81 CTSL (0.46) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL22901710 0.80 CTSL (0.49) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL21390121 0.80 CTSL (0.49) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL23294685 0.80 CTSL (0.49) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL18762235 0.80 CTSL (0.49) CTSLCTSBCTSKOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2023-08-10 US disclosed
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2021-05-06 US disclosed
WO-2019183589-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. (US) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250072-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 CTSL 3987/4885CTSB 3630/4885CTSK 4179/4885
US-20210130308-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 CTSL 3987/4885CTSB 3630/4885CTSK 4179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.